Cyclerion Therapeutics (CYCN) News Today $2.95 +0.06 (+2.08%) (As of 11/1/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Regina Graul, Ph.D., Promoted to Chief Executive OfficerAugust 7, 2024 | globenewswire.comCYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q1 2024May 8, 2024 | investorplace.comSage Therapeutics Stock (NASDAQ:SAGE), Quotes and News SummaryApril 28, 2024 | benzinga.comCyclerion Therapeutics Inc Ordinary Shares CYCNApril 21, 2024 | morningstar.comCYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q4 2023April 5, 2024 | investorplace.comTrading was temporarily halted for "CYCN" at 01:04 PM with a stated reason of "LULD pause."April 4, 2024 | marketbeat.comCyclerion Therapeutics Inc (CYCN)March 6, 2024 | investing.comCyclerion Therapeutics, Inc. (CYCN)February 29, 2024 | uk.finance.yahoo.comTrading was temporarily halted for "CYCN" at 09:02 AM with a stated reason of "LULD pause."February 26, 2024 | marketbeat.comCyclerion Therapeutics Stock (NASDAQ:CYCN) Dividends: History, Yield and DatesFebruary 23, 2024 | benzinga.comTrading was temporarily halted for "CYCN" at 09:12 AM with a stated reason of "LULD pause."December 20, 2023 | marketbeat.comTrading was temporarily halted for "CYCN" at 10:12 AM with a stated reason of "LULD pause."December 19, 2023 | marketbeat.comCyclerion Therapeutics appoints Graul as PresidentDecember 4, 2023 | msn.comCyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge InnovatorNovember 30, 2023 | finance.yahoo.comCyclerion Therapeutics' Market Cap Drops To US$5.0m Leaving Insiders With LossesNovember 28, 2023 | finance.yahoo.comTisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion AssetsJuly 31, 2023 | finance.yahoo.comCYCN - Cyclerion Therapeutics, Inc.June 30, 2023 | ca.finance.yahoo.comCyclerion Therapeutics, Inc.: Cyclerion Regains Compliance with Nasdaq Minimum Bid Price RequirementJune 2, 2023 | finanznachrichten.deCyclerion Therapeutics in compliance with Nasdaq minimum bid price ruleJune 1, 2023 | msn.comTrading was temporarily halted for "CYCN" at 02:05 PM with a stated reason of "LULD pause."May 16, 2023 | marketbeat.comTrading was temporarily halted for "CYCN" at 02:05 PM with a stated reason of "LULD pause."May 16, 2023 | marketbeat.comTrading was temporarily halted for "CYCN" at 12:05 PM with a stated reason of "LULD pause."May 16, 2023 | marketbeat.comTrading was temporarily halted for "CYCN" at 12:05 PM with a stated reason of "LULD pause."May 16, 2023 | marketbeat.comCyclerion Therapeutics, Inc.: Cyclerion Announces Reverse Stock SplitMay 16, 2023 | finanznachrichten.deCyclerion announces 1 for 20 reverse stock splitMay 15, 2023 | msn.comCyclerion Therapeutics to Sell Assets for $81M, CEO Transition To New Spin-Off Private Company Established By Shareholders, New InvestorsMay 12, 2023 | finance.yahoo.comCyclerion Therapeutics, Inc.: Cyclerion Announces Corporate Updates and Q1 2023 Financial ResultsMay 12, 2023 | finanznachrichten.deCyclerion Therapeutics down 6% on spin off agreementMay 12, 2023 | msn.comCyclerion Announces Corporate Updates and Q1 2023 Financial ResultsMay 11, 2023 | finance.yahoo.comCyclerion Announces Definitive Agreement for Zagociguat and CY3018May 11, 2023 | finance.yahoo.comCyclerion Therapeutics, Inc.: Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment AgreementApril 3, 2023 | finanznachrichten.deCyclerion Gets FDA Orphan Designation for Zagociguat in Mitochondrial Diseases >CYCNMarch 27, 2023 | marketwatch.comCyclerion Therapeutics, Inc.: Cyclerion Reports Corporate Update and Full Year 2022 Financial ResultsMarch 23, 2023 | finanznachrichten.deCyclerion Reports Corporate Update and Full Year 2022 Financial ResultsMarch 22, 2023 | finance.yahoo.comWhy American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From YesterdayNovember 23, 2022 | msn.comCyclerion Shares Rise After Spurned Bid for AssetsNovember 22, 2022 | marketwatch.comCyclerion Rejects Unsolicited Proposal To Buy Its AssetsNovember 22, 2022 | markets.businessinsider.comCyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The CompanyNovember 22, 2022 | finance.yahoo.comCyclerion Therapeutics lays off nearly half of workforceOctober 7, 2022 | finance.yahoo.comCyclerion Therapeutics IncSeptember 9, 2022 | reuters.comCyclerion Therapeutics, Inc. (CYCN) Reports Q2 Loss, Misses Revenue EstimatesAugust 9, 2022 | finance.yahoo.comCyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial ResultsAugust 9, 2022 | finance.yahoo.comIs Cyclerion Therapeutics (NASDAQ:CYCN) In A Good Position To Invest In Growth?August 8, 2022 | finance.yahoo.comRecap Of Thursday's Biotech Catalysts - End of The Day SummaryJuly 28, 2022 | msn.comCyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)July 28, 2022 | finance.yahoo.comCyclerion Neurology Candidate Shows Encouraging Action In Preclinical StudiesJune 17, 2022 | finance.yahoo.comCyclerion Therapeutics Posts Positive Study Data for MELAS TreatmentJune 10, 2022 | marketwatch.comAs Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) drops to US$26m market cap, insiders might rethink their US$2.7m stock purchase earlier this yearMay 11, 2022 | finance.yahoo.comCyclerion Therapeutics reports Q1 resultsMay 4, 2022 | seekingalpha.comCyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial ResultsMay 4, 2022 | finance.yahoo.com Get Cyclerion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter. Email Address 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here CYCN Media Mentions By Week CYCN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYCN News Sentiment▼0.000.41▲Average Medical News Sentiment CYCN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYCN Articles This Week▼00▲CYCN Articles Average Week Get Cyclerion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ORGS News Today ESLA News Today ACXP News Today EYEN News Today LPCN News Today ICCC News Today TPST News Today NAII News Today BGXX News Today OCX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CYCN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclerion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclerion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
